ASY: nuclear-led growth supports full-year targets despite Expleo-driven H1 loss
According to TradingView, ASY's nine-month organic revenue rose 2.8%, while H1 EBIT-A margin climbed to 6.4%.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, ASY's nine-month revenue grew 2.8% on an organic basis. The gains were led by the nuclear segment and France. The H1 EBIT-A margin rose to 6.4%.
The company keeps its full-year targets of roughly 3% organic growth and a 7% EBIT-A margin. The source says the H1 net loss reflected a loss from remeasuring Expleo bonds. The source notes that this is an AI-generated summary that may contain inaccuracies, so key figures should be checked against the original document.
why it matters
Investors should weigh two points: steady growth in nuclear energy and maintained full-year guidance despite a loss tied to the remeasurement of Expleo bonds. The next signal will be whether the company delivers on its targets in the second half.
market impact
ASY shares: nuclear growth supports the stock, while the Expleo bond loss weighs on it
- ASY shares mixed — nuclear segment growth supports the stock, while the Expleo bond remeasurement loss weighs on it
tags
instruments
sources
- ASY: Nuclear-led organic growth supports FY targets despite an Expleo-driven H1 loss — TradingView, 27 October 2026 at 16:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗